Blair William & Co. IL Reduces Stock Position in CRISPR Therapeutics AG $CRSP

Blair William & Co. IL lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 48.5% during the second quarter, HoldingsChannel.com reports. The fund owned 35,130 shares of the company’s stock after selling 33,087 shares during the quarter. Blair William & Co. IL’s holdings in CRISPR Therapeutics were worth $1,709,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in CRSP. SVB Wealth LLC purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at about $25,000. Costello Asset Management INC purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at about $27,000. Quantbot Technologies LP boosted its holdings in shares of CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after acquiring an additional 978 shares during the last quarter. GF Fund Management CO. LTD. boosted its holdings in shares of CRISPR Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after acquiring an additional 394 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of CRISPR Therapeutics by 153.3% during the 1st quarter. US Bancorp DE now owns 3,063 shares of the company’s stock valued at $104,000 after acquiring an additional 1,854 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $69.38 on Wednesday. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The company has a market capitalization of $6.31 billion, a P/E ratio of -12.78 and a beta of 1.84. The firm’s 50 day simple moving average is $59.59 and its two-hundred day simple moving average is $49.36.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. During the same quarter in the previous year, the firm earned ($1.49) earnings per share. The company’s revenue for the quarter was up 72.5% on a year-over-year basis. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRSP has been the topic of a number of recent analyst reports. Wells Fargo & Company set a $75.00 price target on shares of CRISPR Therapeutics in a report on Monday. Barclays raised their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Finally, Piper Sandler reissued an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $71.71.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.